BACKGROUND: Management of glioblastoma is complicated by pseudoprogression, a radiological phenomenon mimicking progression. This retrospective cohort study investigated the incidence, prognostic implications, and most clinically appropriate definition of pseudoprogression. METHODS: Consecutive glioblastoma patients treated at the Juravinski Hospital and Cancer Centre, Hamilton, Ontario between 2004 and 2012 with temozolomide chemoradiotherapy and with contrast-enhanced MRI at standard imaging intervals were included. At each imaging interval, patient responses as per the RECIST (Response Evaluation Criteria in Solid Tumors), MacDonald, and RANO (Response Assessment in Neuro-Oncology) criteria were reported. Based on each set of criteria, subjects were classified as having disease response, stable disease, pseudoprogression, or true progression. The primary outcome was overall survival. RESULTS: The incidence of pseudoprogression among 130 glioblastoma patients treated with chemoradiotherapy was 15%, 19%, and 23% as defined by RANO, MacDonald, and RECIST criteria, respectively. Using the RANO definition, median survival for patients with pseudoprogression was 13.0 months compared with 12.5 months for patients with stable disease (hazard ratio [HR]=0.70; 95% confidence interval [CI], 0.35-1.42). Similarly, using the MacDonald definition, median survival for the pseudoprogression group was 11.8 months compared with 12.0 months for the stable disease group (HR=0.86; 95% CI, 0.47-1.58). Furthermore, disease response compared with stable disease was also similar using the RANO (HR=0.52; 95% CI, 0.20-1.35) and MacDonald (HR=0.51: 95% CI, 0.20-1.31) definitions. CONCLUSIONS: Of all conventional glioblastoma response criteria, the RANO criteria gave the lowest incidence of pseudoprogression. Regardless of criteria, patients with pseudoprogression did not have statistically significant difference in survival compared with patients with stable disease.
BACKGROUND: Management of glioblastoma is complicated by pseudoprogression, a radiological phenomenon mimicking progression. This retrospective cohort study investigated the incidence, prognostic implications, and most clinically appropriate definition of pseudoprogression. METHODS: Consecutive glioblastoma patients treated at the Juravinski Hospital and Cancer Centre, Hamilton, Ontario between 2004 and 2012 with temozolomide chemoradiotherapy and with contrast-enhanced MRI at standard imaging intervals were included. At each imaging interval, patient responses as per the RECIST (Response Evaluation Criteria in Solid Tumors), MacDonald, and RANO (Response Assessment in Neuro-Oncology) criteria were reported. Based on each set of criteria, subjects were classified as having disease response, stable disease, pseudoprogression, or true progression. The primary outcome was overall survival. RESULTS: The incidence of pseudoprogression among 130 glioblastoma patients treated with chemoradiotherapy was 15%, 19%, and 23% as defined by RANO, MacDonald, and RECIST criteria, respectively. Using the RANO definition, median survival for patients with pseudoprogression was 13.0 months compared with 12.5 months for patients with stable disease (hazard ratio [HR]=0.70; 95% confidence interval [CI], 0.35-1.42). Similarly, using the MacDonald definition, median survival for the pseudoprogression group was 11.8 months compared with 12.0 months for the stable disease group (HR=0.86; 95% CI, 0.47-1.58). Furthermore, disease response compared with stable disease was also similar using the RANO (HR=0.52; 95% CI, 0.20-1.35) and MacDonald (HR=0.51: 95% CI, 0.20-1.31) definitions. CONCLUSIONS: Of all conventional glioblastoma response criteria, the RANO criteria gave the lowest incidence of pseudoprogression. Regardless of criteria, patients with pseudoprogression did not have statistically significant difference in survival compared with patients with stable disease.
Entities:
Keywords:
Chemoradiotherapy; glioblastoma; magnetic resonance imaging; pseudoprogression.
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Gloria B Roldán; James N Scott; John B McIntyre; Marisa Dharmawardene; Paula A de Robles; Anthony M Magliocco; Elizabeth S Y Yan; Ian F Parney; Peter A Forsyth; J Gregory Cairncross; Mark G Hamilton; Jacob C Easaw Journal: Can J Neurol Sci Date: 2009-09 Impact factor: 2.104
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Elizabeth R Gerstner; Margaret B McNamara; Andrew D Norden; Debra Lafrankie; Patrick Y Wen Journal: J Neurooncol Date: 2009-02-17 Impact factor: 4.130
Authors: Walter Taal; Dieta Brandsma; Hein G de Bruin; Jacoline E Bromberg; Annemarie T Swaak-Kragten; Peter A E Sillevis Smitt; Corine A van Es; Martin J van den Bent Journal: Cancer Date: 2008-07-15 Impact factor: 6.860
Authors: Jennifer L Clarke; Fabio M Iwamoto; Joohee Sul; Katherine Panageas; Andrew B Lassman; Lisa M DeAngelis; Adília Hormigo; Craig P Nolan; Igor Gavrilovic; Sasan Karimi; Lauren E Abrey Journal: J Clin Oncol Date: 2009-06-08 Impact factor: 44.544
Authors: Guangyang Yu; Madison K Butler; Abdalla Abdelmaksoud; Ying Pang; Yu-Ting Su; Zachary Rae; Kimia Dadkhah; Michael C Kelly; Young K Song; Jun S Wei; Masaki Terabe; Ramya Atony; Kelly Mentges; Brett J Theeler; Marta Penas-Prado; John Butman; Kevin Camphausen; Kareem A Zaghloul; Edjah Nduom; Martha Quezado; Kenneth Aldape; Terri S Armstrong; Mark R Gilbert; James L Gulley; Javed Khan; Jing Wu Journal: Front Oncol Date: 2021-01-14 Impact factor: 6.244
Authors: Sebastian F Winter; Eugene J Vaios; Alona Muzikansky; Maria Martinez-Lage; Marc R Bussière; Helen A Shih; Jay Loeffler; Philipp Karschnia; Franziska Loebel; Peter Vajkoczy; Jorg Dietrich Journal: Oncologist Date: 2020-06-18